血腦障壁藥物遞送市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、地區和競爭格局分類，2021-2031年）

全球血腦障壁滲透性輸送市場預計將從 2025 年的 19.5 億美元成長到 2031 年的 26.9 億美元，複合年成長率為 5.51%。

此細分市場包括旨在將治療藥物輸送穿過半透性內皮屏障（該屏障將中樞神經系統與體循環分隔開來）的專用技術和製劑。全球神經退化性疾病盛行率的不斷上升以及對這些傳統上難以治癒的疾病進行非侵入性治療方法的需求，是推動該市場成長的主要因素。世界神經病學聯合會 (WFN) 預測，到 2024 年，神經系統疾病將成為全球首要致殘原因，影響超過 30 億人，凸顯了開發能夠有效治療複雜中樞神經系統疾病的先進給藥系統的緊迫性。

然而，血腦障壁高度複雜的生理特性為市場拓展帶來了巨大挑戰。它天然地阻擋了大多數小分子和大分子藥物。這種選擇性滲透性導致候選藥物在臨床試驗中失敗率極高，因此，工程化載體必須在不影響安全性的前提下可靠地穿過此屏障。因此，如何使藥物在大腦中達到足夠的濃度仍然是研發人員將新型神經治療藥物商業化的主要障礙。

市場促進因素

全球神經退化性疾病和中樞神經系統（CNS）疾病的日益流行是推動血腦障壁（BBB）藥物遞送市場發展的主要因素。不斷成長的患者群體迫切需要有效的治療藥物轉運機制。阿茲海默症和腦腫瘤等疾病日益加重的全球負擔，給藥物研發人員帶來了越來越大的壓力，他們需要克服限制全身治療效果的內皮細胞屏障。根據阿茲海默症協會於2025年4月發布的《2025年阿茲海默症最新進展報告》，目前約有720萬65歲及以上的美國人患有老年失智症失智症，凸顯了腦滲透性治療方法的迫切需求。此外，更廣泛的腫瘤學領域也支持這項需求。全身性癌症經常轉移到中樞神經系統，據美國癌症協會稱，預計到 2025 年，美國將診斷出 2,041,910總合新的癌症病例，這推動了對能夠到達顱內惡性腫瘤的輸送技術的需求。

第二個關鍵促進因素是策略聯盟的興起，這些聯盟加速了藥物遞送平台的商業化進程，透過大量的資金注入和技術協同效應效應，使實驗性、突破性的技術能夠轉化為臨床應用。大型製藥企業正擴大與專業生物技術公司合作，將專有的穿梭平台整合到其大分子藥物研發管線中，從而降低中樞神經系統（CNS）藥物研發的高風險。羅氏日益重視下一代遞送方式就是這一趨勢的一個顯著例證。根據該公司2025年11月發布的新聞稿，Manifold Bio已與羅氏達成一項價值高達20億美元的策略聯盟，共同開發血腦障壁穿梭系統。此類高價值協議驗證了這些遞送系統的商業性潛力，並確保創新的遞送方法能夠獲得必要的投資，最終推向市場。

市場挑戰

血腦障壁的生理複雜性是拓展藥物遞送市場的主要障礙。這種生物防禦機制限制了治療藥物的選擇性進入，使得在中樞神經系統內達到所需的藥物濃度變得極為困難。因此，製藥公司在臨床試驗中經常遭遇挫折，因為設計的載體往往無法在保持安全性和有效性的同時克服這一屏障。這項技術障礙增加了研發所需的時間和資金，使得神經系統藥物研發計畫比其他治療領域的風險顯著更高。

這種高風險狀況與新型治療方法的商業化率較低有直接關係。當藥物遞送機制無法有效輸送藥物時，整個研發項目往往會停滯，對研發者造成重大經濟損失。根據美國藥品研究與製造商協會（PhRMA）預測，到2024年，由於中樞神經系統（CNS）研究固有的難度，進入開發平臺的新型神經系統藥物的臨床成功率將低於6%。如此低的核准機率限制了新產品的上市，並限制了全球市場的潛在收入成長。

市場趨勢

受體介導的胞吞轉運技術平台的進步正在從根本上改變市場格局，使大分子治療藥物能夠通過內源性穿梭系統跨越內皮屏障。研發人員正逐步摒棄侵入性給藥方式，轉而尋求活化天然轉運機制並繞過外排放泵的方法，例如設計能夠與轉鐵蛋白等受體結合的雙特異性抗體。隨著大型製藥公司尋求將這些穿梭平台整合到其生物製藥產品線中，以確保治療藥物的可及性，這項技術變革正在推動高價值整合。根據艾伯維公司2024年12月發布的新聞稿“艾伯維完成對Ariada Therapeutics的收購”，該公司以14億美元收購了Ariada Therapeutics，主要目的是獲得其專有的MODEL平台。此平台利用高親和性轉鐵蛋白受體偶聯物遞送多種中樞神經系統（CNS）候選藥物。

同時，基於奈米技術的載體系統的廣泛應用，使得將包括mRNA和基因療法在內的脆弱基因藥物直接遞送至腦組織成為可能。研究日益聚焦於具有最佳化表面化學性質的脂質奈米顆粒（LNP），這些顆粒能夠穿透血腦障壁的緊密連接，且不影響所包裹藥物的穩定性。這些先進的載體克服了病毒載體的局限性，能夠降低免疫抗原性，並為複雜的製劑提供更高的載藥量。在2025年2月發表於《自然·材料》（Nature Materials）雜誌的一篇題為“用於中樞神經系統mRNA遞送的血腦障壁穿透性脂質奈米顆粒”的研究中，西奈山伊坎醫學院的一個研究團隊成功開發了一種新型脂質奈米顆粒系統，與現有的批准製劑相比，該系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的核准系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統實現了更高效的FDAmRNA系統。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球血腦障壁藥物遞送市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 透過技術手段（特洛伊木馬方法、雙特異性抗體RMT方法、血腦障壁滲透性改善、被動擴散等）
  • 依應用領域（阿茲海默症、癲癇、帕金森氏症、多發性硬化症、韓特氏症、腦腫瘤等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美血腦障壁藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲血腦障壁藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區血腦障壁藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲血腦障壁藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲血腦障壁藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球血腦障壁藥物遞送市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Ossianix Inc.
• Insightec Ltd.
• F. Hoffmann-La Roche Ltd
• JCR Pharmaceuticals Co., Ltd.
• Lauren Sciences LLC
• Bioasis Technologies Inc.
• Ceres Brain Therapeutics
• Nanomerics Ltd.
• NEUWAY Pharma GmbH
• Genervon Biopharmaceuticals LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Drug Delivery Across Blood Brain Barrier Market is projected to expand from USD 1.95 Billion in 2025 to USD 2.69 Billion by 2031, reflecting a compound annual growth rate of 5.51%. This sector encompasses specialized technologies and formulations designed to transport therapeutic agents through the semi-permeable endothelial boundary separating the central nervous system from systemic circulation. The market is fundamentally supported by the increasing global prevalence of neurodegenerative diseases and the critical necessity for non-invasive mechanisms to treat conditions previously considered inaccessible. According to the World Federation of Neurology, in 2024, neurological disorders were the leading cause of disability worldwide and affected over three billion individuals, underscoring the urgent demand for advanced delivery systems capable of ensuring therapeutic efficacy for complex central nervous system conditions.

However, the profound physiological complexity of the blood-brain barrier represents a significant challenge impeding market expansion, as it naturally excludes the vast majority of small and large molecule drugs. This selective permeability results in an exceptionally high failure rate for drug candidates during clinical trials, as engineered carriers must successfully traverse the barrier without compromising safety. Consequently, the scientific difficulty in achieving sufficient drug concentration within the brain remains a primary obstacle for developers aiming to commercialize novel neurological therapies.

Market Driver

The rising global prevalence of neurodegenerative and CNS disorders serves as the primary catalyst propelling the drug delivery across the blood-brain barrier market, as the escalating patient population intensifies the urgent need for effective therapeutic transport mechanisms. As the global burden of conditions like Alzheimer's disease and brain tumors expands, pharmaceutical developers are under increasing pressure to overcome the endothelial impediments that restrict the efficacy of systemic treatments. According to the Alzheimer's Association's '2025 Alzheimer's Disease Facts and Figures' report released in April 2025, an estimated 7.2 million Americans aged 65 and older are currently living with Alzheimer's dementia, highlighting the critical demand for brain-penetrant therapies. Furthermore, the broader oncology sector reinforces this necessity, as systemic cancers frequently metastasize to the central nervous system; according to the American Cancer Society, in 2025, a total of 2,041,910 new cancer cases are projected to be diagnosed in the United States, driving the requirement for delivery technologies that can reach intracranial malignancies.

Strategic collaborations to accelerate delivery platform commercialization have emerged as a second decisive driver, enabling the translation of experimental barrier-crossing technologies into clinical realities through significant capital infusion and technical synergy. Large pharmaceutical entities are increasingly partnering with specialized biotech firms to integrate proprietary shuttle platforms with their large molecule pipelines, thereby mitigating the high risks associated with CNS drug development. A notable instance of this trend occurred when Roche strengthened its commitment to next-generation delivery modalities; according to Manifold Bio in a November 2025 corporate press release, the company entered a strategic partnership with Roche worth up to $2 billion to develop blood-brain barrier shuttles leveraging in vivo design technologies. Such high-value agreements validate the commercial potential of these delivery systems and ensure that innovative transport methodologies receive the investment necessary to reach the market.

Market Challenge

The physiological complexity of the blood-brain barrier constitutes a primary restraint on the expansion of the drug delivery market. This biological defense mechanism selectively restricts the entry of therapeutic agents, leading to significant difficulties in achieving necessary drug concentrations within the central nervous system. As a result, pharmaceutical companies encounter frequent setbacks during clinical trials, as engineered carriers often fail to navigate the barrier while maintaining safety and efficacy standards. This technical hurdle increases the time and capital required for development, making neurological programs significantly riskier than those in other therapeutic areas.

This elevated risk profile directly correlates with reduced commercialization rates for novel therapies. When delivery mechanisms fail to transport drugs effectively, the entire development program is often terminated, resulting in substantial financial losses for developers. According to the Pharmaceutical Research and Manufacturers of America, in 2024, the inherent difficulties in CNS research resulted in a clinical success rate of less than 6 percent for new neurological medicines entering the development pipeline. This low probability of approval limits the introduction of new products and constrains the potential revenue growth for the global market.

Market Trends

The advancement of receptor-mediated transcytosis platforms is fundamentally altering the market by enabling the transport of large-molecule therapeutics through the endothelial boundary via endogenous shuttle systems. Developers are moving beyond invasive delivery methods, instead engineering bispecific antibodies that bind to receptors such as transferrin to trigger natural transport mechanisms and bypass efflux pumps. This technological shift is driving high-value consolidation as major pharmaceutical companies seek to integrate these shuttle platforms into their biologic pipelines to ensure therapeutic reach. According to AbbVie, in the 'AbbVie Completes Acquisition of Aliada Therapeutics' press release from December 2024, the company acquired Aliada Therapeutics for $1.4 billion primarily to secure its proprietary MODEL platform, which utilizes high-affinity transferrin receptor binders to deliver diverse CNS drug candidates.

Concurrently, the widespread adoption of nanotechnology-based carrier systems is expanding the possibilities for delivering fragile genetic medicines, including mRNA and gene therapies, directly to brain tissue. Research is increasingly focusing on lipid nanoparticles (LNPs) with optimized surface chemistries that can navigate the blood-brain barrier's tight junctions without compromising the stability of the encapsulated payload. These advanced carriers are overcoming the limitations of viral vectors by offering reduced immunogenicity and higher cargo capacity for complex formulations. According to the Icahn School of Medicine at Mount Sinai, in the study 'Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system' published in 'Nature Materials' in February 2025, researchers successfully developed a novel lipid nanoparticle system that achieved superior mRNA delivery efficiency to the brain compared to existing FDA-approved formulations.

Key Market Players

• Ossianix Inc.
• Insightec Ltd.
• F. Hoffmann-La Roche Ltd
• JCR Pharmaceuticals Co., Ltd.
• Lauren Sciences LLC
• Bioasis Technologies Inc.
• Ceres Brain Therapeutics
• Nanomerics Ltd.
• NEUWAY Pharma GmbH
• Genervon Biopharmaceuticals LLC

Report Scope

In this report, the Global Drug Delivery Across Blood Brain Barrier Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Delivery Across Blood Brain Barrier Market, By Technology

• Trojan Horse Approach
• Bispecific Antibody RMT Approach
• Increasing the Permeability of BBB
• Passive Diffusion
• Others

Drug Delivery Across Blood Brain Barrier Market, By Application

• Alzheimer's Disease
• Epilepsy
• Parkinson's Disease
• Multiple Sclerosis
• Hunter's Syndrome
• Brain Cancer
• Others

Drug Delivery Across Blood Brain Barrier Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Delivery Across Blood Brain Barrier Market.

Available Customizations:

Global Drug Delivery Across Blood Brain Barrier Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug Delivery Across Blood Brain Barrier Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Trojan Horse Approach, Bispecific Antibody RMT Approach, Increasing the Permeability of BBB, Passive Diffusion, Others)
  • 5.2.2. By Application (Alzheimer's Disease, Epilepsy, Parkinson's Disease, Multiple Sclerosis, Hunter's Syndrome, Brain Cancer, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Drug Delivery Across Blood Brain Barrier Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application

7. Europe Drug Delivery Across Blood Brain Barrier Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
  • 7.3.2. France Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application

8. Asia Pacific Drug Delivery Across Blood Brain Barrier Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
  • 8.3.2. India Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application

9. Middle East & Africa Drug Delivery Across Blood Brain Barrier Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. South America Drug Delivery Across Blood Brain Barrier Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Drug Delivery Across Blood Brain Barrier Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ossianix Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Insightec Ltd.
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. JCR Pharmaceuticals Co., Ltd.
• 15.5. Lauren Sciences LLC
• 15.6. Bioasis Technologies Inc.
• 15.7. Ceres Brain Therapeutics
• 15.8. Nanomerics Ltd.
• 15.9. NEUWAY Pharma GmbH
• 15.10. Genervon Biopharmaceuticals LLC

16. Strategic Recommendations

17. About Us & Disclaimer